Why your "normal" B12 may not be normal
The standard total serum B12 test measures all cobalamin circulating in the blood. Most labs report a reference range of approximately 200-900 pg/mL (or 150-700 pmol/L), and anything above the lower limit gets a checkmark. The problem: approximately 70-80% of circulating B12 is bound to haptocorrin, a carrier protein that does not deliver B12 to cells. Only the 20-30% bound to transcobalamin II (called holotranscobalamin, or active B12) actually reaches your tissues[1].
This means you can have a total B12 of 300 pg/mL — well within range — while your active B12 is depleted. Studies have shown that functional B12 deficiency (detected by elevated methylmalonic acid) can occur at total B12 levels up to 400 pg/mL[2]. The "gray zone" between 200-400 pg/mL is diagnostically unreliable without confirmatory markers.
The diagnostic cascade: active B12, MMA, and homocysteine
Active B12 (holotranscobalamin)
Active B12 is the earliest marker to decline when B12 stores are depleting. It falls before total B12 drops below range and before MMA rises. If your active B12 is below 35-40 pmol/L, cellular deficiency is likely even if total B12 appears adequate[1].
Methylmalonic acid (MMA)
MMA is a metabolic byproduct that accumulates when B12 is insufficient for the enzyme methylmalonyl-CoA mutase. It is the most specific functional marker of intracellular B12 deficiency. An elevated MMA (above 0.4 umol/L, though some labs use 0.27-0.37) confirms that B12 deficiency is affecting cellular metabolism, regardless of what total B12 shows[2].
One caveat: MMA is cleared by the kidneys, so it can be elevated in kidney disease independently of B12 status. In patients with reduced eGFR, MMA interpretation requires more nuance.
Homocysteine
Homocysteine is elevated in both B12 and folate deficiency. It is less specific than MMA for B12 alone, but elevated homocysteine (above 12-15 umol/L) combined with elevated MMA strongly points to B12 deficiency. Elevated homocysteine on its own is also an independent cardiovascular risk factor[3].
| Marker | What it tells you | Deficiency signal |
|---|---|---|
| Total B12 | All B12 in blood (active + inactive) | < 200 pg/mL is deficient; 200-400 is a gray zone |
| Active B12 (holoTC) | B12 available to cells | < 35-40 pmol/L |
| Methylmalonic acid | Functional B12 status at cellular level | > 0.4 umol/L (some labs > 0.27) |
| Homocysteine | B12 or folate insufficiency | > 12-15 umol/L |
Neurological symptoms: the quiet emergency
B12 is essential for myelin synthesis — the insulating sheath around nerve fibers. When B12 is insufficient, myelin degrades, and neurons cannot conduct signals properly. The neurological consequences can be severe and, critically, can occur without any hematological abnormalities (no anemia, normal MCV)[4].
Neurological manifestations of B12 deficiency include:
- Peripheral neuropathy: Tingling, numbness, or "pins and needles" in hands and feet — often symmetric and starting distally
- Balance and gait disturbance: Due to posterior column (proprioception) involvement
- Cognitive impairment: Brain fog, difficulty concentrating, memory problems
- Depression and mood changes: B12 is required for the synthesis of serotonin and dopamine
- Subacute combined degeneration: In severe, prolonged deficiency — degeneration of the dorsal and lateral columns of the spinal cord. This can become irreversible[4]
Who is at risk
Vegans and vegetarians
B12 is found naturally only in animal products: meat, fish, eggs, and dairy. No plant food contains bioavailable B12 in meaningful amounts (despite claims about fermented foods and algae — these contain B12 analogues that may actually compete with real B12 for absorption). Studies consistently show that without supplementation, 52% of vegans and 7-20% of lacto-ovo vegetarians are B12 deficient[5].
The body stores 2-5 mg of B12, primarily in the liver. This buffer means that deficiency can take 2-5 years to develop after ceasing animal product intake — creating a dangerous delay between dietary change and symptoms.
Metformin users
Metformin, the most widely prescribed diabetes medication worldwide, reduces B12 absorption. The mechanism involves interference with the calcium-dependent uptake of the B12-intrinsic factor complex in the terminal ileum. The landmark Diabetes Prevention Program Outcomes Study (DPPOS) — an RCT — found that long-term metformin use was associated with a 19% reduction in B12 levels over 4.3 years, with significantly higher rates of deficiency and anemia[6].
The American Diabetes Association now recommends periodic B12 monitoring in metformin users, particularly those on high doses or with long duration of use[7].
GLP-1 receptor agonist users
Emerging evidence suggests that GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) may also impair B12 absorption. These medications slow gastric emptying, alter gastric acid secretion, and may affect intrinsic factor production. Studies with liraglutide have shown reduced B12 levels in some patients[8]. The risk is likely compounded when GLP-1 agonists are combined with metformin, which is common clinical practice.
Older adults
B12 absorption requires adequate gastric acid and intrinsic factor. Atrophic gastritis — the progressive loss of acid-secreting cells in the stomach — affects 10-30% of adults over 60[9]. This reduces the body's ability to liberate B12 from food proteins, even when dietary intake is sufficient. Proton pump inhibitors (PPIs), widely used in older adults, further suppress acid and compound the problem.
Proton pump inhibitor (PPI) users
Long-term PPI use (omeprazole, pantoprazole, etc.) suppresses gastric acid, which is needed to release B12 from food proteins. A large cohort study found that 2+ years of PPI use was associated with a 65% increased risk of B12 deficiency[10].
Pernicious anemia
Pernicious anemia is an autoimmune condition in which antibodies destroy the gastric parietal cells that produce intrinsic factor — the protein required for B12 absorption. It is the most common cause of severe B12 deficiency and requires lifelong B12 supplementation, usually by injection[11].
Methylcobalamin vs cyanocobalamin
The two most common supplemental forms of B12 are cyanocobalamin (synthetic) and methylcobalamin (the active coenzyme form). The debate between them is largely overblown, but the nuances matter:
- Cyanocobalamin: Synthetic, extremely stable, inexpensive, and the form used in most clinical trials. The body must convert it to the active forms (methylcobalamin and adenosylcobalamin) by removing the cyanide moiety. The trace cyanide released is negligible in healthy individuals. This is the most studied and most cost-effective form[12].
- Methylcobalamin: The bioactive coenzyme form used in the methionine synthase reaction (which converts homocysteine to methionine). It does not require conversion and may be preferable in individuals with impaired conversion pathways (e.g., certain MTHFR polymorphisms) or in those with chronic kidney disease where cyanide clearance may be reduced[12].
- Hydroxocobalamin: Used in injections. Longer half-life than cyanocobalamin, preferred for pernicious anemia in many countries.
- Adenosylcobalamin: The mitochondrial form, used in the methylmalonyl-CoA mutase reaction. Less commonly available as a supplement.
Practical recommendation: For most people, either cyanocobalamin or methylcobalamin works well. Methylcobalamin is a reasonable default if you want to skip the conversion step. The key factor is actually taking it consistently, not which form you choose.
Supplementation protocols
| Situation | Route | Dose |
|---|---|---|
| Vegan/vegetarian maintenance | Oral sublingual | 1,000-2,000 mcg daily or 2,500 mcg 2x/week |
| Mild deficiency (B12 200-400, MMA borderline) | Oral sublingual | 1,000-2,000 mcg daily for 8-12 weeks, then retest |
| Moderate deficiency (B12 < 200 or elevated MMA) | Oral high-dose or IM injection | 1,000-2,000 mcg oral daily, or IM 1,000 mcg weekly x 4, then monthly |
| Severe deficiency or pernicious anemia | IM injection | 1,000 mcg IM every other day for 2 weeks, then weekly x 4, then monthly |
| Metformin user (prevention) | Oral | 1,000 mcg daily |
Absorption note: Oral B12 at high doses (1,000+ mcg) is absorbed even in people with impaired intrinsic factor, because approximately 1% is absorbed via passive diffusion across the intestinal wall. This means that 1,000 mcg oral delivers approximately 10 mcg — more than the daily requirement of 2.4 mcg[13].
The homocysteine-cardiovascular connection
B12, folate, and vitamin B6 are all required for the metabolism of homocysteine. When any of these are deficient, homocysteine accumulates. Elevated homocysteine (hyperhomocysteinemia) is an established independent risk factor for cardiovascular disease, stroke, and venous thromboembolism[3].
The relationship is well-documented observationally, though intervention trials (supplementing B vitamins to lower homocysteine) have shown mixed results for reducing cardiovascular events. The current consensus is that homocysteine is a marker of risk and B vitamin adequacy, and correcting deficiency is warranted, but homocysteine-lowering alone (in B-replete individuals) has not been conclusively shown to reduce events[14].
Testing frequency
- High-risk groups (vegans, vegetarians, metformin users, PPI users, GLP-1 users, adults over 60): Annual testing of total B12 + MMA (or active B12)
- After starting supplementation: Retest at 8-12 weeks to confirm levels are responding
- Once stable and supplementing consistently: Annual testing is sufficient
- If neurological symptoms are present: Test immediately with total B12, active B12, MMA, and homocysteine. Do not wait.